Poisoned in the Womb: When Medicine's Mistakes Echo Through Generations - Jill Escher (#19)
Jill Escher's discovery that her mother received weekly synthetic hormone injections during pregnancy in 1965 led her to connect prenatal steroid exposure to the modern surge in both autism and gender dysphoria. The episode carries direct relevance for British listeners: DES and similar anti-miscarriage drugs were prescribed on the NHS, the Cass Review flagged the autism–gender dysphoria overlap, and Escher's argument about institutional silence will resonate with anyone who has followed the Tavistock story. She suggests the crisis runs deeper — and further back in time — than the culture war framing usually allows.
Jill Escher is an autism advocate and president of the National Council on Severe Autism in the United States. Raising two sons with profound autism led her to dig into her family's medical history, where she found that in 1965 her mother had received weekly injections of synthetic steroid hormones during pregnancy — a common clinical practice at the time. Escher has spent years tracing what she believes are the multigenerational consequences of that decision for neurodevelopment. The most infamous of these drugs is DES, a synthetic oestrogen prescribed across the Western world, including on the NHS, to prevent miscarriage. Its harms became undeniable — elevated cancer rates, reproductive abnormalities, neurological differences in those exposed in the womb — but Escher argues the reckoning is still incomplete. She connects DES and similar anti-miscarriage drugs, some still in clinical use until 2023, to the steep rise in both autism diagnoses and gender dysphoria now seen among young people. The mechanism, she suggests, lies in altered gene expression passed between generations. The overlap between autism and gender dysphoria is one of the most consistent findings in the gender medicine literature, and one the Cass Review took seriously. Dr Hilary Cass's 2024 report noted that a significant proportion of young people referred to gender services in England had co-occurring neurodevelopmental conditions. Escher's hypothesis offers that overlap a possible biological explanation — not cultural contagion alone, but altered neurodevelopment with roots in prenatal exposure to exogenous hormones, decades before the patients themselves were born. Britain knows what delayed medical accountability looks like. The thalidomide disaster, the contaminated blood scandal — the NHS carries those histories. Escher's argument that institutions have been slow to connect the dots on prenatal hormone exposure will sound recognisable to anyone who has followed the Tavistock story. She asks who bears responsibility when evidence accumulates inconveniently, and what scientific courage looks like in practice. The episode explores why this line of research has not been pursued more aggressively, and what it would take to change that. For British listeners tracking the reform of gender services — the closure of the Tavistock, the commissioning of new regional hubs, the search for a genuinely evidence-based clinical pathway — Escher's work carries an unsettling implication. If the surge in gender dysphoria among young people is at least partly rooted in altered prenatal neurodevelopment rather than ideology alone, the response cannot be limited to reforming clinics. Escher calls for research, recognition and accountability. Those are demands the British debate has barely begun to grapple with.
